Background/Objectives: Health-related quality of life (HRQoL) is critical in patients with hepatocellular carcinoma (HCC). It has become a key endpoint in the evaluation of new therapies, including atezolizumab + bevacizumab (Atezo + Bev) therapy. Methods: This study explored the factors associated with treatment efficacy, treatment duration, and overall survival (OS) in patients with advanced HCC undergoing Atezo + Bev therapy. We included 58 consecutive patients with HCC receiving Atezo + Bev from 19 November 2020, to 28 December 2023, who were followed up until the end of the study or death. We analyzed the relationships between baseline characteristics, adverse events (AEs), and HRQoL and efficacy, OS, and treatment duration. Results: The demographic (older men) and baseline characteristics (Child–Pugh score of 5, Barcelona Clinic Liver Cancer Stage C) were consistent with those of previous studies. The treatment demonstrated promising efficacy with a disease control rate of 71.2%, but HRQoL scores in five functional domains and seven symptoms worsened significantly within the first 3 months. Notably, better baseline cognitive and physical function scores and absence of severe (grade ≥ 2) hypoalbuminemia were associated with an improved objective response rate, longer treatment duration, and better OS. Conclusions: These findings underscore the importance of monitoring and managing treatment-related AEs and maintaining the HRQoL. They also highlight the crucial and reassuring role of multidisciplinary care in enhancing treatment outcomes in this cohort.
背景/目的：在肝细胞癌（HCC）患者中，健康相关生活质量（HRQoL）至关重要，已成为评估包括阿替利珠单抗联合贝伐珠单抗（Atezo + Bev）在内的新疗法的关键终点。方法：本研究探讨了接受Atezo + Bev治疗的晚期HCC患者中与疗效、治疗持续时间和总生存期（OS）相关的因素。我们纳入了2020年11月19日至2023年12月28日期间连续接受Atezo + Bev治疗的58例HCC患者，并随访至研究结束或患者死亡。我们分析了基线特征、不良事件（AEs）和HRQoL与疗效、OS及治疗持续时间之间的关系。结果：人口统计学特征（老年男性）和基线特征（Child–Pugh评分为5分，巴塞罗那临床肝癌分期为C期）与既往研究一致。该疗法显示出良好的疗效，疾病控制率为71.2%，但在治疗前3个月内，五个功能领域和七项症状的HRQoL评分显著恶化。值得注意的是，较好的基线认知和身体功能评分以及未出现严重（≥2级）低白蛋白血症与更高的客观缓解率、更长的治疗持续时间和更好的OS相关。结论：这些发现强调了监测和管理治疗相关AEs以及维持HRQoL的重要性，同时也凸显了多学科护理在改善该队列患者治疗结局方面关键且令人安心的作用。
肿瘤(癌症)患者之家